TRT(600085)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥5,143,069,726.63, representing a 30.08% increase compared to ¥3,953,698,821.02 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥523,355,606.08, reflecting a 30.85% increase from ¥399,961,569.63 in the previous year[4] - The basic earnings per share for Q1 2023 was ¥0.382, an increase of 30.82% compared to ¥0.292 in the previous year[5] - Operating profit for Q1 2023 was ¥995,843,502.23, up 44.7% from ¥687,941,569.74 in Q1 2022[18] - The total comprehensive income for the first quarter of 2023 was CNY 772,106,058.66, an increase from CNY 548,283,148.97 in the same period of 2022, representing a growth of approximately 40.8%[19] Cash Flow and Assets - The net cash flow from operating activities reached ¥1,145,427,938.13, up 22.62% from ¥934,100,363.26 in the same period last year[5] - The company's cash and cash equivalents as of March 31, 2023, amount to approximately RMB 12.57 billion, an increase from RMB 11.62 billion at the end of 2022, reflecting a growth of about 8.15%[14] - Total current assets increased to approximately RMB 21.47 billion from RMB 20.56 billion, marking a growth of about 4.43% year-over-year[14] - The net increase in cash and cash equivalents for Q1 2023 was CNY 946,802,643.32, compared to CNY 780,999,899.77 in Q1 2022, showing an increase of approximately 21.2%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 67,051, with the largest shareholder, Beijing Tongrentang (Group) Co., Ltd., holding 719,308,540 shares, representing 52.45% of total shares[10] - The company has no pledged, marked, or frozen shares among its top shareholders, indicating a stable ownership structure[10] - The largest institutional investor, China Industrial Bank Co., Ltd., holds 53,320,470 shares, representing 3.89% of total shares[10] - The company has not reported any significant changes in its shareholder relationships or actions among major shareholders[11] Liabilities and Equity - Total liabilities rose to ¥8,689,204,417.95 in Q1 2023, compared to ¥8,590,423,576.47 in Q1 2022, marking an increase of 1.2%[16] - Shareholders' equity attributable to the parent company was ¥12,308,524,557.01, up 4.22% from ¥11,807,275,548.61 at the end of the previous year[5] - The company's total equity reached ¥19,225,133,163.58 in Q1 2023, an increase from ¥18,463,699,667.91 in Q1 2022, reflecting a growth of 4.1%[16] Operational Insights - The company reported a 30.08% increase in operating revenue due to increased demand in the pharmaceutical market and significant sales growth from subsidiaries[9] - The accounts receivable increased by 25.10% due to the management of customer credit limits, with the overall balance being reasonable and controllable[9] - Research and development expenses for Q1 2023 were ¥45,194,023.47, a 39.1% increase from ¥32,473,405.94 in Q1 2022[18] - Selling expenses in Q1 2023 amounted to ¥934,153,949.48, up 19.2% from ¥784,042,047.02 in Q1 2022[18] Inventory and Non-Current Assets - Inventory decreased to approximately RMB 6.40 billion from RMB 6.69 billion, a decline of about 4.31%[14] - The company reported a total non-current asset value of approximately RMB 6.05 billion as of March 31, 2023, compared to RMB 6.07 billion at the end of 2022, showing a slight decrease of about 0.33%[14] Future Outlook - Future outlook includes continued investment in R&D and market expansion strategies to sustain growth momentum[17] - The report does not indicate any new product launches or technological developments during the quarter[12]